Miseq genetic analyzer

Manufactured by Illumina

Sourced in United States

The MiSeq genetic analyzer is a laboratory equipment designed for DNA sequencing. It is capable of generating sequence data from DNA samples.

Automatically generated - may contain errors

Lab products found in correlation

Variantstudio v3, by Illumina (2 mentions) Cfx96 touch, by Bio-Rad (1 mentions) Abi prism 3130, by Thermo Fisher Scientific (1 mentions) Nextera xt library prep kit, by Illumina (1 mentions) Bigdye terminator cycle sequencing kit, by Thermo Fisher Scientific (1 mentions) Nextera xt index kit, by Illumina (1 mentions) Qiasymphony dsp dna mini kit, by Qiagen (1 mentions) Fragment analyzer, by Agilent Technologies (1 mentions)

4 protocols using miseq genetic analyzer

Mutational Landscape in Multiple Myeloma

Check if the same lab product or an alternative is used in the 5 most similar protocols

The mutational status of KRAS, NRAS, and BRAF genes was studied in bone marrow samples of 34 patients. In 16 patients, in addition to bone marrow, mutations in these genes were evaluated in plasma ctDNA. All three localizations (plasma, bone marrow, and plasmacytoma) were studied in three patients. The mutational profile of the KRAS and NRAS genes was studied by Sanger sequencing on the Nanophor 05 genetic analyzer (Institute for Analytical Instrumentation Russian Academy of Science, Russia) and by the NGS on the MiSeq genetic analyzer (Illumina, San Diego, CA, USA). The BRAF V600E mutation was determined by real-time allele-specific PCR with the device CFX96 Touch (Bio-Rad, Hercules, CA, USA).
Statistical analysis was carried out using frequency analysis (using conjugacy tables and the Fisher criterion).

Soloveva M., Solovev M., Nikulina E., Risinskaya N., Biderman B., Yakutik I., Obukhova T, & Mendeleeva L. (2023). Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma. Genes, 14(2), 351.

+ Open protocol

+ Expand

Genome Sequencing of Viral Strains

Check if the same lab product or an alternative is used in the 5 most similar protocols

The nucleotide sequences of the HA gene fragment were determined using an ABI Prism 3130 automatic sequencer and the BigDye Terminator Cycle Sequencing kit (Applied Biosystems, Waltham, MA, USA) according to the manufacturer’s instructions. Genome-wide sequencing was performed using a MiSeq genetic analyzer (Illumina, Hayward, CA, USA) according to the manufacturer’s instructions (for the resequencing of small genomes). The commercial Nextera XT Library Prep Kit (Illumina, Hayward, CA, USA) and Nextera XT Index Kits (Illumina, Hayward, CA, USA) were used to prepare the libraries. The viral genome was built in GS Reference Mapper v2.7 and GS De Novo Assembler v2.7, and the genome sequencing results were deposited in the GenBank database (Table 1).

Zinyakov N., Andriyasov A., Zhestkov P., Kozlov A., Nikonova Z., Ovchinnikova E., Grekhneva A., Shcherbakova L., Andreychuk D., Sprygin A., Prokhvatilova L, & Chvala I. (2022). Analysis of Avian Influenza (H5N5) Viruses Isolated in the Southwestern European Part of the Russian Federation in 2020–2021. Viruses, 14(12), 2725.

+ Open protocol

+ Expand

Genomic DNA Isolation and Variant Analysis

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Plasma blood samples were collected in Vacutainer tubes. Subsequently, genomic DNA was isolated from whole blood using the QIAsymphony DSP DNA Mini Kit (Qiagen, Germantown, MD, USA) and used to prepare indexed libraries using the Trusight Cancer Panel – Nextera DNA Flex Pre-Enrichment Library Prep (Illumina, San Diego, USA). Libraries were sequenced on a MiSeq genetic analyzer (Illumina, Inc., San Diego, CA), according to the manufacturer’s protocols. Annotation was performed against the human reference genome GRCh38 using VariantStudio V.3 (Illumina, Inc., San Diego, CA). Based on the data generated from this software, alterations were identified as pathogenic when classified as disease causing or as variants of unknown significance (VUS) when evidence regarding their pathogenicity was either conflicting or limited. The validation of results was performed according to criteria of American College of Medical Genetics – ACMG (8 (link)) and National Comprehensive Cancer Network (NCCN) guidelines.

Andrikopoulou A., Zografos E., Apostolidou K., Kyriazoglou A., Papatheodoridi A.M., Kaparelou M., Koutsoukos K., Liontos M., Dimopoulos M.A, & Zagouri F. (2022). Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis. Frontiers in Oncology, 12, 1030786.

+ Open protocol

+ Expand

Targeted Cancer Gene Sequencing from Plasma

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Plasma blood samples were collected in Vacutainer tubes. Within 4 hours after collection, plasma was separated from whole blood samples through centrifugation for 10 min at 3000 rpm at room temperature and stored at −80°C until further use. Genomic DNA was extracted from whole blood using the QIAsymphony DSP DNA Mini Kit and used to prepare indexed libraries to target the sequence of 42 cancer predisposing genes using the Trusight Cancer Panel – Nextera DNA Flex Pre-Enrichment Library Prep (Illumina, San Diego, USA) (Supplementary Table 2). Libraries were qualitatively and quantitatively evaluated using a Fragment Analyzer (Advanced Analytical Technologies, Heidelberg, Germany) and sequenced on a MiSeq genetic analyzer (Illumina, Inc., San Diego, CA), according to the manufacturer’s protocols. Annotation was performed against the human reference genome GRCh38 using VariantStudio V.3 (Illumina). The validation of results was performed according to criteria of American College of Medical Genetics – ACMG (12 (link)) and NCCN guidelines.

Andrikopoulou A., Chatzinikolaou S., Kyriopoulos I., Bletsa G., Kaparelou M., Liontos M., Dimopoulos M.A, & Zagouri F. (2022). The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis. Frontiers in Oncology, 11, 797505.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!